Switch to Etravirine from PI-Based Regimen ETRA-SWITCH STUDY



Switch to Etravirine from PI-Based Regimen ETRA-SWITCH: Design

Study Design: ETRA-SWITCH


 Background: Open label, randomized phase 3b trial that enrolled patients with suppressed viral load while taking a ritonavir-boosted PI plus 2NRTIs and examined the efficacy and safety of switching the ritonavir-boosted PI to etravirine

Inclusion Criteria (n = 43)

- On PI >12 months
- HIV RNA <50 copies/mL for >6 months
- No NRTI or NNRTI resistance
- No prior virologic failure with prior regimen
- Patients had dyslipidemia OR use of lipid lowering medication OR GI disturbance OR persistent dissatisfaction with current regimen

Treatment Arms


- Switch PI in regimen to etravirine 400 mg/day
- Continue current PI-based ART regimen





Switch to Etravirine from PI-Based Regimen ETRA-SWITCH: Result


Week 48: Virologic Response (ITT Analysis, Missing = Failure)





Switch to Etravirine from PI-Based Regimen ETRA-SWITCH: Result

Week 48: Change in Plasma Lipids from Baseline








Switch to Etravirine from PI-Based Regimen ETRA-SWITCH: Result

Patient Satisfaction Scores





Switch to Etravirine from PI-Based Regimen ETRA-SWITCH: Conclusions

Conclusion: "Switch from a PI-based regimen to a once-daily combination based on ETR maintained undetectable VL during 48 weeks in virologically suppressed HIV-infected patients while lipid profile and patient satisfaction improved significantly."



The National HIV Curriculum is an AIDS Education and Training Center (AETC) Program resource funded by the United States Health Resources and Services Administration. The project is led by the University of Washington and the AETC National Coordinating Resource Center.

The content in this slide set does not represent the official views of the U.S. Department of Health and Human Services, Health Resources & Services Administration.



